CLRB - Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Cellectar Biosciences (CLRB) announces that it has received notification of formal grant of the patent titled, "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles" by the Eurasian, Australian and Mexican patent authorities.The patent provides composition of matter and use protection for the company’s proprietary phospholipid-ether ((PLE)) analogs as a targeted delivery vehicle in combination with a broad range of commonly used chemotherapeutic classes such as alkaloids, nucleoside analogs, as well as other classes of small molecule chemotherapeutic agents.The cancer-targeting PLE delivery vehicle serves as the foundation for the company’s research, development and pipeline including CLR 131, its lead product candidate.CLR 131 is currently in multiple clinical studies, including a pivotal registrational study in Waldenstrom’s macroglobulinemia, and a Phase 2b study in multiple myeloma.Shares up more than 2% premarket.

For further details see:

Cellectar gets notification of formal grant from Australian and Mexican patent authorities